Yesterday, March 8, 2016, 87 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $567.44 to $9,409,592.36.

Highlighted Stocks Traded by Insiders:

Medicines (MDCO) - FREE Research Report

O'Connor William Bernard, who is Chief Financial Officer at Medicines, sold 8,617 shares at $34.39 on March 8, 2016. Following this transaction, the Chief Financial Officer owned 19,724 shares meaning that the stake was reduced by 30.4% with the 8,617-share transaction.

The shares most recently traded at $33.40, down $0.99, or 2.97% since the insider transaction. Historical insider transactions for Medicines go as follows:

  • 4-Week # shares sold: 3,305
  • 12-Week # shares sold: 3,305
  • 24-Week # shares sold: 3,305

The average volume for Medicines has been 1.1 million shares per day over the past 30 days. Medicines has a market cap of $2.4 billion and is part of the health care sector and drugs industry. Shares are down 9.27% year-to-date as of the close of trading on Tuesday.

The Medicines Company provides medicines for patients in acute and intensive care hospitals worldwide. Currently, there are 7 analysts who rate Medicines a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on MDCO - FREE

TheStreet Quant Ratings

rates Medicines as a

hold

. The company's strengths can be seen in multiple areas, such as its solid stock price performance and largely solid financial position with reasonable debt levels by most measures. However, as a counter to these strengths, we also find weaknesses including feeble growth in the company's earnings per share, deteriorating net income and disappointing return on equity. Get the full

Medicines Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

DexCom (DXCM) - FREE Research Report

Kahn Barbara, who is Director at DexCom, sold 5,000 shares at $67.04 on March 8, 2016. Following this transaction, the Director owned 45,804 shares meaning that the stake was reduced by 9.84% with the 5,000-share transaction.

The shares most recently traded at $63.65, down $3.39, or 5.33% since the insider transaction. Historical insider transactions for DexCom go as follows:

  • 4-Week # shares sold: 3,560
  • 12-Week # shares sold: 27,837
  • 24-Week # shares sold: 71,079

The average volume for DexCom has been 962,800 shares per day over the past 30 days. DexCom has a market cap of $5.6 billion and is part of the health care sector and health services industry. Shares are down 19.3% year-to-date as of the close of trading on Tuesday.

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring systems in the United States and internationally. Currently, there are 11 analysts who rate DexCom a buy, 1 analyst rates it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on DXCM - FREE

TheStreet Quant Ratings

rates DexCom as a

sell

. Among the areas we feel are negative, one of the most important has been an overall disappointing return on equity. Get the full

DexCom Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Wright Medical Group (WMGI) - FREE Research Report

Mowry David H, who is Executive VP and COO at Wright Medical Group, sold 13,500 shares at $17.34 on March 8, 2016. Following this transaction, the Executive VP and COO owned 160,311 shares meaning that the stake was reduced by 7.77% with the 13,500-share transaction.

The shares most recently traded at $17.14, down $0.20, or 1.2% since the insider transaction. Historical insider transactions for Wright Medical Group go as follows:

  • 4-Week # shares sold: 4.5 million
  • 12-Week # shares sold: 4.5 million
  • 24-Week # shares sold: 4.5 million

The average volume for Wright Medical Group has been 889,500 shares per day over the past 30 days. Wright Medical Group has a market cap of $1.8 billion and is part of the health care sector and health services industry. Shares are down 29.78% year-to-date as of the close of trading on Tuesday.

Wright Medical Group N.V., a medical device company, designs, manufactures, markets, and sells orthopedic products in the United States, Europe, and internationally. Currently, there are 10 analysts who rate Wright Medical Group a buy, no analysts rate it a sell, and 5 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on WMGI - FREE

TheStreet Quant Ratings

rates Wright Medical Group as a

sell

. The company's weaknesses can be seen in multiple areas, such as its weak operating cash flow and generally disappointing historical performance in the stock itself. Get the full

Wright Medical Group Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.